CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cumberland Pharmaceuticals (CPIX) Reports Q4 Loss of $0.05/sh
March 7, 2023 4:38 PM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 EPS of ($0.05). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.07 million.
For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.
... More